News
IKT
1.700
+7.59%
0.120
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Pfizer (PFE) and Inhibikase Therapeutics (IKT)
TipRanks · 3d ago
Weekly Report: what happened at IKT last week (0126-0130)?
Weekly Report · 5d ago
Weekly Report: what happened at IKT last week (0119-0123)?
Weekly Report · 01/26 09:11
INHIBIKASE THERAPEUTICS INC <IKT.O>: BOFA GLOBAL RESEARCH INITIATES COVERAGE WITH BUY RATING; PRICE OBJECTIVE $6
Reuters · 01/21 14:48
Inhibikase Therapeutics Price Target Announced at $6.00/Share by B of A Securities
Dow Jones · 01/21 14:03
Inhibikase Therapeutics Initiated at Buy by B of A Securities
Dow Jones · 01/21 14:03
B of A Securities Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $6
Benzinga · 01/21 13:52
Inhibikase Therapeutics initiated with a Buy at BofA
TipRanks · 01/21 11:31
U.S. RESEARCH ROUNDUP-IBM, KLA, WEX
Reuters · 01/21 08:26
Weekly Report: what happened at IKT last week (0112-0116)?
Weekly Report · 01/19 09:12
Weekly Report: what happened at IKT last week (0105-0109)?
Weekly Report · 01/12 09:12
Weekly Report: what happened at IKT last week (1229-0102)?
Weekly Report · 01/05 09:11
Weekly Report: what happened at IKT last week (1222-1226)?
Weekly Report · 12/29/2025 09:11
Dynavax, Inhibikase and More: Stocks Trending by Analysts
TipRanks · 12/27/2025 09:02
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 12/26/2025 17:05
Inhibikase Therapeutics Coverage Assumed by HC Wainwright & Co. at Buy
Dow Jones · 12/26/2025 11:19
Inhibikase Therapeutics Price Target Announced at $8.00/Share by HC Wainwright & Co.
Dow Jones · 12/26/2025 11:19
Inhibikase Therapeutics: Late-Stage IKT-001 PAH Program and De-Risked 505(b)(2) Pathway Support Buy Rating and $8 Target
TipRanks · 12/26/2025 11:15
HC Wainwright & Co. Assumes Inhibikase Therapeutics at Buy, Announces Price Target of $8
Benzinga · 12/26/2025 11:10
INHIBIKASE THERAPEUTICS INC <IKT.O>: H.C. WAINWRIGHT ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $8
Reuters · 12/26/2025 11:09
More
Webull provides a variety of real-time IKT stock news. You can receive the latest news about Inhibikase Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).